Introduction and objectives Bedaquiline and delamanid were centrally commissioned by NHS England for management of MDR and XDR-TB, within specified criteria (including age 16-65, pulmonary disease, discussion in BTS MDR-TB forum and six months usage) in Aug 2015. We sought to determine ease of availability, obstacles faced and off licence use by prescribing centres. Methods An electronic survey was sent to the leads or nominated deputy of MDR-TB centres in England, and the responses analysed using the Surveymonkey web tool. Results Response rate was 64% (18/28). Of the respondents, 8 centres (44%) had not used the drugs since Aug 2015. Of the remainder, indications in all cases were either drug resistance (90% of centres) or intolerance (70% of centres). Intolerance was usually hearing loss from second line injectable agents and tendonitis from fluoroquinolones; a minority of patients also could not tolerate prolonged linezolid. 90% of cases had been discussed in the BTS MDR-TB forum; the exception was a case of non tuberculous mycobacterial(NTM) disease(M. abscessus) which was discussed with other NTM experts. There was minimal delay (<2 weeks) between the MDR-TB forum decision to use the drugs and NHS England approval when used for licenced indications; one delay occurred when requesting an extension beyond 6 months (7 weeks delay). There was minimal delay (<2 weeks) between NHS England approval and the patient actually receiving the drug. Both drugs were used in the same patient by two centres (20%). The drugs had been used 'off licence' by 6/10 centres. Details in Table 1 . Free text responses highlighted difficulty in obtaining the outcome of individualised funding request decisions, difficulty obtaining funding for children (being paid for by the children's hospital in one case), and two rejections of the use in NTM disease. Conclusions Access to bedaquiline and delamanid within licenced indications seems to have minimal delay. Difficulties may arise when the drug needs to be used for 6 months. Problems are also reported with funding in children. There is emerging evidence of benefit in difficult NTM disease; this is an unlicensed indication that may expand in the future. Consideration may need to be given to a forum for difficult NTM disease. Aim Ethambutol is one of the first-line drugs used to treat tuberculosis (TB) but its side effects include optic neuropathy, causing sight loss and changes in colour-vision. Early detection can mean any toxicity is reversible. Careful monitoring of sight is therefore required in patients taking ethambutol. After a patient irreversibly lost his sight from ethambutol toxicity and a successful claim was made against the hospital, more robust methods of monitoring eyesight were needed in patients taking ethambutol. Method Currently in our department, all patients being started on ethambutol are referred to the ophthalmology department for baseline eye testing of visual acuity and colour vision. They are tested again at 4-6 months if they remain on ethambutol past 2 months. In between this, we previously relied on the patient reporting any change in vision to the TB team who would then arrange additional formal testing. To improve monitoring, we purchased two apps-a Munsell D15 Colour Vision Test and a LogMAR acuity test-to be used on an iPad. Four members of clinic staff were trained to use the apps. All patients on prolonged ethambutol now have their vision tested at all TB clinic appointments (usually monthly).
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